0

Close
 
New
New
2023
Exosome Diagnostic And Therapeutic Market

Exosome Diagnostic and Therapeutic Market

by Application (Diagnostic, Therapeutic), by Product (Instrument, Reagent, Software), by End User (Cancer Institute, Hospital, Diagnostic Center, Others): Global Opportunity Analysis and Industry Forecast, 2021-2030

LS : Diagnostics and Biotech
Report Code: A01396
Aug 2023 | Pages: 110
Tables: 120
Charts: 56

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

Exosome Diagnostic And Therapeutic Market Statistics - 2030

The global exosome diagnostic and therapeutic market size was valued at $224.34 million in 2020, and is projected to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosome is the membrane-bound vesicle that is synthesized in the extracellular compartment of the eukaryotic cells. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Biomolecules, including proteins, metabolites, and nucleic acids are delivered by exosomes into target cells effectively to alter their biological response. Exosomes are engineered to deliver diverse therapeutic payloads, including short interfering ribonucleic acid (RNAs), antisense oligonucleotides, chemotherapeutic agents, and immune modulators, with an ability to direct their delivery to a desired target. Exosome vesicle-based liquid biopsy is used for potential utilization in diagnosis and determining the prognosis of patients with cancer and other disease.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global exosome diagnostic and therapeutic market. The COVID-19 pandemic has stressed healthcare systems in the world and increased the need for advanced hospitals. Implementation of the spread of COVID-19 infection increased the need for molecular diagnosis and drive the growth of the market.

Exosome Diagnostic and Therapeutic Market

The exosome diagnostic and therapeutic market share is primarily driven by increase in prevalence of chronic disease, infectious disease, autoimmune disease and cancer and surge in demand for molecular diagnosis. In addition, ongoing advance exosome technology in drug development and discovery yields valuable information regarding the heterogeneity and biological function and enhances the ability to harness the therapeutic and diagnostic potential for cancer & infectious disease. Thus, advancement in technology in healthcare sector propels the growth of the exosome diagnostic market, and exosome therapeutic market.

Increase in demand for drug therapies and surge in R&D activities in pharmaceutical and biopharmaceutical field which is stimulated by the potential of exosome technologies as diagnostic and therapeutic tools are used for the treatment of various diseases, including neurodegeneration, cardiovascular dysfunction, and cancer. Increase in potential application of exosome in cancer diagnosis and development of translational precision medicine increase the use of exosome diagnostic and therapeutic industry and surge the growth of exosome diagnostic market, and exosome therapeutic market.

The key factor for the exosome diagnostic and therapeutic market growth includes increase in use of multifunctional property of exosome therapy for chronic heart failure, Alzheimer disease , Parkinson’s disease , and cancer, including breast, prostate, liver, and lung cancer which , in turn, boosts to growth of the market . Furthermore, on August 2020, Aethlon Medical, a healthcare company, announced the collaboration with University of Pittsburgh on National Institute of Health Grant for treatment of head and neck cancer. Exosomes are nanosized particles that are released in large quantities from cancer cells and carry complement of a tumor's genetic and protein cargo, which fuel cancer growth and immune suppression.

In addition, in April 2020, Exosome Diagnostics, a biotechnology company, announced the launch of ExoDx Prostate test kit at-home. ExoDx Prostate (EPI) test is a urine-based, genomic test that helps to detect prostate cancer . This liquid biopsy test recently received coverage in the VA Healthcare system through a General Services Administration (GSA) award and is included in the National Cancer Comprehensive Network (NCCN) guidelines for early detection in men .

Exosomes Diagnostic And Therapeutic Market Segmentation 

The exosome diagnostic and therapeutic market is segmented into application, product, end user and region. Depending on the application, it is divided into diagnostic and therapeutic applications.  By the product, it is fragmented into instrument, reagents, and software. According to end user, it is segmented into cancer institute,  hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations).

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

By application, the diagnostic segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for early diagnosis. However, the therapeutics segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for drug development.

Exosome Diagnostic and Therapeutic Market
By Application

Your browser does not support the canvas element.

Diagnostic segment would witness the fastest growth, registering a CAGR of 28.8% during the forecast period.

Get more information on this report : Request Sample Pages

Depending on product, the reagents segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to increase in need for molecular diagnosis and surge in R&D activities for the purpose of diagnosis. However, the instrument segment is expected to witness considerable growth during the forecast period, owing to advancements in R&D activities in the healthcare sector and increase in number of key manufacturer.

Exosome Diagnostic and Therapeutic Market
By Product

Your browser does not support the canvas element.

Software segment Enterprises segment was the highest revenue contributor during the forecast period.

Get more information on this report : Request Sample Pages

According to end user, the cancer institute segment was the major contributor in 2020, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of cancer, increase in number of hospitals and surge in initiatives by government for development of healthcare infrastructure. However, the diagnostic center segment is expected to witness considerable growth during the forecast period, owing to increase in prevalence of chronic disease and surge in demand for molecular diagnosis.

Exosome Diagnostic and Therapeutic Market
By End User

Your browser does not support the canvas element.

Cancer Institute segment held the major share of 29.7% throughout the forecast period.

Get more information on this report : Request Sample Pages

Region wise, North America garnered a major share in the exosome diagnostic and therapeutic market in 2020, and is expected to be dominant during the exosome diagnostic and therapeutic market forecast period, owing to rise in prevalence of chronic disorder, increase in number of product launch for exosome therapeutics, surge in presence of key players, and development of R&D activities in pharmaceutical and biopharmaceutical sector in the region. However, Asia-Pacific is expected to register highest CAGR of 30.3% from 2021 to 2030, owing to increase in prevalence of chronic and infectious disorder, growth in health care expenditures, rise in number of exosome diagnostic and therapeutic industry and surge in demand for molecular diagnosis.

Exosome Diagnostic and Therapeutic Market
By Region

2030
North America 
Europe
Asia-Pacific
LAMEA

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

The key players operating in the global exosome diagnostic and therapeutic market include Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark). The other players in the value chain include 101BIO, AMS Biotechnology Limited, Therapeutic Solutions International, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, ExoCyte Therapeutics Pte Ltd., Cell Guidance Systems LLC, BioRegenerative Sciences, Inc., Evomic Science LLC, and Norgen Biotek Corp.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies

 Exosome Diagnostic and Therapeutic Market Report Highlights

Aspects Details
Market Size By 2030 USD 2.9 billion
Growth Rate CAGR of 29.4%
Forecast period 2020 - 2030
Report Pages 110
By Application
  • Diagnostic
  • Therapeutic
By Product
  • Instrument
  • Reagent
  • Software
By End User
  • Cancer Institute
  • Hospital
  • Diagnostic Center
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players NanoSomix, Inc, System Biosciences, Inc, Malvern Instruments Ltd, Capricor Therapeutics, Inc., Aethlon Medical, Inc., Thermo Fisher Scientific, Inc., Exiqon A/S, NX Pharmagen, Inc., Exosome Diagnostic, Inc., Sistemic Ltd

Analyst Review

This section provides various opinions of the top-level CXOs in the clinical area of exosome-based research examination and studies. In accordance to several interviews conducted, utilization of exosome isolation instrument is expected to witness a significant rise with increase in  focus on life science research, rise in diagnostic procedures for cancer, and surge in innovative and advanced applications of isolation kits.

Moreover, remarkable technological advancements in the exosome isolation kits and reagents to provide advanced extraction procedures from the body fluids surge the demand for molecular diagnosis drive the growth of the market. According to the CXOs of leading companies operating in this market, increase in prevalence of cancer, surge in technological advancements, and rise in emphasis on early diagnosis of cancer are some of the major factors driving market growth.

However, lack of awareness regarding the use of exosome therapeutics and stringent regulations for the approval of products used in exosome-based research hamper the growth of the market. Presently, the diagnostic application is the largest segment in the global exosome diagnostic and therapeutic market. According to the CXOs, rise in incidences of cancer, growth in geriatric population, and surge in initiatives by various government associations for screening of cancer boost the growth of the exosome diagnostic and therapeutic market.

According to the CXO’s, cancer institutes are the major end users in the exosome diagnostic and therapeutic market. This is due to the increase in focus of cancer prevention & treatment and rise in government supports in the form of funding to the cancer institutes. As per CXOs, North America is expected to dominate the global exosome diagnostic and therapeutic market during the forecast period, followed by Europe.

 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Low bargaining power of suppliers

      • 3.3.2. Low threat of new entrants

      • 3.3.3. Low threat of substitutes

      • 3.3.4. Low intensity of rivalry

      • 3.3.5. Low bargaining power of buyers

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Increase in prevalence of chronic diseases
        • 3.4.1.2. Increase in prevalence of cancer
        • 3.4.1.3. Rise in number of geriatric populations

      • 3.4.2. Restraints

        • 3.4.2.1. Lack of product approvals for exosome diagnostic and therapeutic technique

      • 3.4.3. Opportunities

        • 3.4.3.1. Rise in adoption of key strategies

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Diagnostic

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Therapeutic

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

  • CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Instrument

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Reagent

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Software

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

  • CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Cancer Institute

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Hospital

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

    • 6.4. Diagnostic Center

      • 6.4.1. Key market trends, growth factors and opportunities

      • 6.4.2. Market size and forecast, by region

      • 6.4.3. Market share analysis by country

    • 6.5. Others

      • 6.5.1. Key market trends, growth factors and opportunities

      • 6.5.2. Market size and forecast, by region

      • 6.5.3. Market share analysis by country

  • CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Application

      • 7.2.3. Market size and forecast, by Product

      • 7.2.4. Market size and forecast, by End User

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Application
          • 7.2.5.1.3. Market size and forecast, by Product
          • 7.2.5.1.4. Market size and forecast, by End User
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Application
          • 7.2.5.2.3. Market size and forecast, by Product
          • 7.2.5.2.4. Market size and forecast, by End User
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Application
          • 7.2.5.3.3. Market size and forecast, by Product
          • 7.2.5.3.4. Market size and forecast, by End User

    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Application

      • 7.3.3. Market size and forecast, by Product

      • 7.3.4. Market size and forecast, by End User

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Application
          • 7.3.5.1.3. Market size and forecast, by Product
          • 7.3.5.1.4. Market size and forecast, by End User
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Application
          • 7.3.5.2.3. Market size and forecast, by Product
          • 7.3.5.2.4. Market size and forecast, by End User
        • 7.3.5.3. U.K.
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Application
          • 7.3.5.3.3. Market size and forecast, by Product
          • 7.3.5.3.4. Market size and forecast, by End User
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Application
          • 7.3.5.4.3. Market size and forecast, by Product
          • 7.3.5.4.4. Market size and forecast, by End User
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Application
          • 7.3.5.5.3. Market size and forecast, by Product
          • 7.3.5.5.4. Market size and forecast, by End User
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Application
          • 7.3.5.6.3. Market size and forecast, by Product
          • 7.3.5.6.4. Market size and forecast, by End User

    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Application

      • 7.4.3. Market size and forecast, by Product

      • 7.4.4. Market size and forecast, by End User

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Application
          • 7.4.5.1.3. Market size and forecast, by Product
          • 7.4.5.1.4. Market size and forecast, by End User
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Application
          • 7.4.5.2.3. Market size and forecast, by Product
          • 7.4.5.2.4. Market size and forecast, by End User
        • 7.4.5.3. Rest of Asia-Pacific
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Application
          • 7.4.5.3.3. Market size and forecast, by Product
          • 7.4.5.3.4. Market size and forecast, by End User

    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Application

      • 7.5.3. Market size and forecast, by Product

      • 7.5.4. Market size and forecast, by End User

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Application
          • 7.5.5.1.3. Market size and forecast, by Product
          • 7.5.5.1.4. Market size and forecast, by End User
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Application
          • 7.5.5.2.3. Market size and forecast, by Product
          • 7.5.5.2.4. Market size and forecast, by End User
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Application
          • 7.5.5.3.3. Market size and forecast, by Product
          • 7.5.5.3.4. Market size and forecast, by End User
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Application
          • 7.5.5.4.3. Market size and forecast, by Product
          • 7.5.5.4.4. Market size and forecast, by End User

  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2020

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Aethlon Medical, Inc.

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Key strategic moves and developments

    • 9.2. Exosome Diagnostic, Inc.

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Key strategic moves and developments

    • 9.3. NanoSomix, Inc

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

    • 9.4. Thermo Fisher Scientific, Inc.

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

      • 9.4.6. Business performance

    • 9.5. Malvern Instruments Ltd

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

    • 9.6. System Biosciences, Inc

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

    • 9.7. NX Pharmagen, Inc.

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

    • 9.8. Sistemic Ltd

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

    • 9.9. Capricor Therapeutics, Inc.

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. Exiqon A/S

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

  • LIST OF TABLES

  • TABLE 01. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 02. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC, BY REGION, 2020-2030 ($MILLION)
    TABLE 03. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR THERAPEUTIC, BY REGION, 2020-2030 ($MILLION)
    TABLE 04. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 05. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR INSTRUMENT, BY REGION, 2020-2030 ($MILLION)
    TABLE 06. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR REAGENT, BY REGION, 2020-2030 ($MILLION)
    TABLE 07. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
    TABLE 08. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 09. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY REGION, 2020-2030 ($MILLION)
    TABLE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY REGION, 2020-2030 ($MILLION)
    TABLE 11. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY REGION, 2020-2030 ($MILLION)
    TABLE 12. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
    TABLE 13. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION, 2020-2030 ($MILLION)
    TABLE 14. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 15. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 16. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 17. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 18. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 19. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 20. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 21. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 22. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 23. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 24. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 25. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 26. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 27. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 28. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 29. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 30. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 31. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 32. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 33. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 34. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 35. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 36. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 37. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 38. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 39. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 40. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 41. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 42. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 43. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 44. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 45. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 46. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 47. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 48. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 49. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 50. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 51. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 52. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 53. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 54. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 55. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 56. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 57. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 58. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 59. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 60. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 61. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 62. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 63. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 64. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 65. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
    TABLE 66. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 67. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 68. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 69. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 70. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 71. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 72. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 73. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 74. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 75. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
    TABLE 76. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
    TABLE 77. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
    TABLE 78. AETHLON MEDICAL, INC.: KEY EXECUTIVES
    TABLE 79. AETHLON MEDICAL, INC.: COMPANY SNAPSHOT
    TABLE 80. AETHLON MEDICAL, INC.: PRODUCT SEGMENTS
    TABLE 81. AETHLON MEDICAL, INC.: PRODUCT PORTFOLIO
    TABLE 82. AETHLON MEDICAL, INC.: KEY STRATERGIES
    TABLE 83. EXOSOME DIAGNOSTIC, INC.: KEY EXECUTIVES
    TABLE 84. EXOSOME DIAGNOSTIC, INC.: COMPANY SNAPSHOT
    TABLE 85. EXOSOME DIAGNOSTIC, INC.: PRODUCT SEGMENTS
    TABLE 86. EXOSOME DIAGNOSTIC, INC.: PRODUCT PORTFOLIO
    TABLE 87. EXOSOME DIAGNOSTIC, INC.: KEY STRATERGIES
    TABLE 88. NANOSOMIX, INC: KEY EXECUTIVES
    TABLE 89. NANOSOMIX, INC: COMPANY SNAPSHOT
    TABLE 90. NANOSOMIX, INC: PRODUCT SEGMENTS
    TABLE 91. NANOSOMIX, INC: PRODUCT PORTFOLIO
    TABLE 92. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
    TABLE 93. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
    TABLE 94. THERMO FISHER SCIENTIFIC, INC.: PRODUCT SEGMENTS
    TABLE 95. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
    TABLE 96. MALVERN INSTRUMENTS LTD: KEY EXECUTIVES
    TABLE 97. MALVERN INSTRUMENTS LTD: COMPANY SNAPSHOT
    TABLE 98. MALVERN INSTRUMENTS LTD: PRODUCT SEGMENTS
    TABLE 99. MALVERN INSTRUMENTS LTD: PRODUCT PORTFOLIO
    TABLE 100. SYSTEM BIOSCIENCES, INC: KEY EXECUTIVES
    TABLE 101. SYSTEM BIOSCIENCES, INC: COMPANY SNAPSHOT
    TABLE 102. SYSTEM BIOSCIENCES, INC: PRODUCT SEGMENTS
    TABLE 103. SYSTEM BIOSCIENCES, INC: SERVICE SEGMENTS
    TABLE 104. SYSTEM BIOSCIENCES, INC: PRODUCT PORTFOLIO
    TABLE 105. NX PHARMAGEN, INC.: KEY EXECUTIVES
    TABLE 106. NX PHARMAGEN, INC.: COMPANY SNAPSHOT
    TABLE 107. NX PHARMAGEN, INC.: PRODUCT SEGMENTS
    TABLE 108. NX PHARMAGEN, INC.: PRODUCT PORTFOLIO
    TABLE 109. SISTEMIC LTD: KEY EXECUTIVES
    TABLE 110. SISTEMIC LTD: COMPANY SNAPSHOT
    TABLE 111. SISTEMIC LTD: PRODUCT SEGMENTS
    TABLE 112. SISTEMIC LTD: PRODUCT PORTFOLIO
    TABLE 113. CAPRICOR THERAPEUTICS, INC.: KEY EXECUTIVES
    TABLE 114. CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT
    TABLE 115. CAPRICOR THERAPEUTICS, INC.: SERVICE SEGMENTS
    TABLE 116. CAPRICOR THERAPEUTICS, INC.: PRODUCT PORTFOLIO
    TABLE 117. EXIQON A/S: KEY EXECUTIVES
    TABLE 118. EXIQON A/S: COMPANY SNAPSHOT
    TABLE 119. EXIQON A/S: PRODUCT SEGMENTS
    TABLE 120. EXIQON A/S: PRODUCT PORTFOLIO

  • LIST OF FIGURES

  • FIGURE 1.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET SEGMENTATION
    FIGURE 2.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030
    FIGURE 3.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,BY APPLICATION,2020(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 15.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,BY PRODUCT,2020(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF INSTRUMENT EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 17.COMPARATIVE SHARE ANALYSIS OF REAGENT EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF SOFTWARE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 19.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,BY END USER,2020(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CANCER INSTITUTE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTER EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF OTHERS EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030(%)
    FIGURE 24.EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION,2020
    FIGURE 25.U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 26.CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 27.MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 28.GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 29.FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 30.U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 31.ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 32.SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 33.REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 34.JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 35.CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 36.REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 37.BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 38.SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 39.SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 40.REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030($MILLION)
    FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 44.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 45.COMPETITIVE DASHBOARD
    FIGURE 46.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 47.AETHLON MEDICAL, INC..: NET SALES ,($MILLION)
    FIGURE 48.EXOSOME DIAGNOSTIC, INC..: NET SALES ,($MILLION)
    FIGURE 49.NANOSOMIX, INC.: NET SALES ,($MILLION)
    FIGURE 50.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
    FIGURE 51.MALVERN INSTRUMENTS LTD.: NET SALES ,($MILLION)
    FIGURE 52.SYSTEM BIOSCIENCES, INC.: NET SALES ,($MILLION)
    FIGURE 53.NX PHARMAGEN.: NET SALES ,($MILLION)
    FIGURE 54.SISTEMIC LTD.: NET SALES ,($MILLION)
    FIGURE 55.CAPRICOR THERAPEUTICS, INC..: NET SALES ,($MILLION)
    FIGURE 56.EXIQON A/S.: NET SALES ,($MILLION)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of exosome diagnostic and therapeutic market is $224.3 million in 2020.

A. The forecast period in the report is from 2021 to 2030

A. The market value of exosome diagnostic and therapeutic Market in 2021 was $288.3 million

A. The base year for the report is 2020.

A. Yes, exosome diagnostic and therapeutic companies are profiled in the report

A. The top companies that hold the market share in exosome diagnostic and therapeutic market are Aethlon Medical, Inc, Exosome Diagnostics Inc., NanoSomix Inc., Thermo Fisher Scientific Inc., Malvern Instruments Ltd., System Biosciences Inc, NX Pharmagen, Sistemic Inc., Capricor Therapeutics, and Exiqon A/S.

A. The key trends in the exosome diagnostic and therapeutic market are increase in prevalence of chronic disease, infectious disease, autoimmune disease and cancer and surge in demand for molecular diagnosis.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Exosome Diagnostic And Therapeutic Market

Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)

  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Aug 2024 - Aug 2025)

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers